Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
Articolo
Data di Pubblicazione:
2020
Abstract:
The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2-6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guérin immunotherapy (BCG)induction. To date, there are no studies comparing post-BCG reTURB with the classic pre-BCG approach. The aim of this study was to assess whether the performance of reTURB after BCG induction in T1HG bladder cancer is related to potential oncological benefits.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
BCG; bladder cancer; reTURB
Elenco autori:
Krajewski, Wojciech; Moschini, Marco; Nowak, Łukasz; Poletajew, Sławomir; Tukiendorf, Andrzej; Afferi, Luca; Teoh, Jeremy; Muilwijk, Tim; Joniau, Steven; Tafuri, Alessandro; Antonelli, Alessandro; Gozzo, Alessandra; Mari, Andrea; Di Trapani, Ettore; Hendricksen, Kees; Alvarez-Maestro, Mario; Serrano, Andrea Rodriguez; Simone, Giuseppe; Zamboni, Stefania; Simeone, Claudio; Marconi, Maria Cristina; Mastroianni, Riccardo; Ploussard, Guillaume; Rajwa, Paweł; Laukhtina, Ekaterina; Zdrojowy-Wełna, Aleksandra; Kołodziej, Anna; Paradysz, Andrzej; Tully, Karl; Krajewska, Joanna; Piszczek, Radosław; Xylinas, Evanguelos; Zdrojowy, Romuald
Link alla scheda completa:
Pubblicato in: